BioSpace News Archive

Policy

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Ipsen and Medison Pharma are pleased to announce the Health Canada approval for Bylvay™ for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis, a progressive and life-threatening liver disease.

November 13, 2023
·
13 min read
Business

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Enanta Pharmaceuticals, Inc. announced that it plans to report its financial results for its fiscal fourth quarter and full year ended September 30, 2023 after the U.S. market closes on November 20, 2023.

November 13, 2023
·
1 min read
Drug Development

Precision BioSciences Presents Late-Breaking Data Highlighting Preclinical Efficacy and Safety of PBGENE-HBV for Chronic Hepatitis B at AASLD’s The Liver Meeting 2023

Precision BioSciences, Inc. announced that the company will present late-breaking data at the American Association for the Study of Liver Diseases’ The Liver Meeting being held in Boston, MA.

November 13, 2023
·
10 min read
Genetown

New Healthcare Professional Component of Let’s Talk About LGSOC to Raise Awareness of Low-Grade Serous Ovarian Cancer as a Distinct and Different Form of Ovarian Cancer Requiring Tailored Resources and Treatment Approach

Verastem Oncology announced the launch of the new healthcare professional component of Let’s Talk About LGSOC, designed to support clinicians in the diagnosis and management of low-grade serous ovarian cancer.

November 13, 2023
·
4 min read
Business

Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates

Milestone Pharmaceuticals Inc. reported financial results for the third quarter ended September 30, 2023, and provided a clinical and corporate update.

November 13, 2023
·
13 min read
Drug Development

Incendia Therapeutics Appoints Wendye Robbins, M.D., as Chief Executive Officer and Doses First Patient in Phase 1b Clinical Trial of PRTH-101, a Novel DDR1 Inhibitor

Incendia Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment, announced the appointment of Wendye Robbins, M.D., as Chief Executive Officer.

November 13, 2023
·
4 min read
Business

Leap Therapeutics Reports Third Quarter 2023 Financial Results

Leap Therapeutics, Inc., a biotechnology company focused on developing targeted and immuno-oncology therapeutics, reported financial results for the third quarter ended September 30, 2023.

November 13, 2023
·
10 min read
Business

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

CervoMed Inc., a clinical stage company focused on developing treatments for degenerative diseases of the brain, announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights.

November 13, 2023
·
14 min read
Antibe Reports Q2 2024 Interim Financial and Operating Results

Antibe Therapeutics Inc., a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, has filed its financial and operating results for the fiscal quarter ended September 30, 2023.

November 13, 2023
·
5 min read
Drug Development

Abcuro Initiates Part B of Registrational Phase 2/3 MUSCLE Clinical Trial of Ulviprubart (ABC008) for the Treatment of Inclusion Body Myositis

Abcuro, Inc. announced initiation of Part B of the registrational Phase 2/3 MUSCLE clinical study, an ongoing clinical trial of ulviprubart for the treatment of inclusion body myositis.

November 13, 2023
·
3 min read